



**Oregon Prescription Drug Affordability Board (PDAB) Rescheduled Regular Meeting
Friday, January 26, 2024
Minutes**

Approved by the board on Feb. 21, 2024

Web link to the meeting video: <https://youtu.be/QwzBR2ON6NU>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20240126-PDAB-document-package.pdf>

Call to order and roll call: Chair Akil Patterson called the meeting to order at 1:00 pm and roll was called.

Board members present: Chair Akil Patterson, Vice Chair Shelley Bailey, Dr. Amy Burns, Dr. Daniel Hartung, Robert Judge, John Murray (arrived at 1:32 pm)

Absent: None

Approval of minutes: Robert Judge made the motion and Amy Burns provided a second to approve the minutes on [Pages 3-5](#) in the agenda packet with the following correction: “Board Member John Murray declared a potential conflict of interest due to his ownership of a pharmacy and based on his consultation with the Oregon Government Ethics Commission.” View the approval in the meeting video at minute [00:00:53](#).

MOTION to approve the minutes as amended.

Board Vote:

Yes: Robert Judge, Amy Burns, Daniel Hartung, Vice Chair Shelley Bailey, Chair Akil Patterson

No: None

Absent for the vote: John Murray

Motion passed 5-0

Program update by Executive Director Ralph Magrish. View the executive director’s report in the meeting video at minute [00:02:15](#).

Board affordability review of Tresiba: The chair led the board in the affordability review of Tresiba, which included drug-specific public comment, board discussion, and potential motion to include Tresiba on the list of insulin products that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 6-27](#) of the agenda packet. View the video of the board discussion at minute [00:07:24](#).

Board affordability review of Tresiba FlexTouch: The chair led the board in the affordability review of Tresiba FlexTouch, which included drug-specific public comment, board discussion, and potential motion to include Tresiba FlexTouch on the list of insulin products that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 6-27](#) of the agenda packet. View the video of the board discussion at minute [00:29:42](#).

Board affordability review of Humulin R U-500 KwikPen: The chair led the board in the affordability review of Humulin R U-500 KwikPen, which included drug-specific public comment, board discussion,



and potential motion to include Humulin R U-500 KwikPen on the list of insulin products that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 28-47](#) of the agenda packet. View the video of the board discussion and vote at minute [00:52:40](#). Robert Judge made a motion and Amy Burns provided a second.

MOTION to include Humulin R U-500 KwikPen on the list of insulin products that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.

Board Vote:

Yes: Amy Burns, Daniel Hartung, Robert Judge, John Murray, Vice Chair Shelley Baily, Chair Akil Patterson

No: None

Motion passed 6-0

Announcements: View the announcements in the meeting video at minute [01:25:00](#).

Public comment: Chair Patterson called on those who signed up to speak to the board. There were two requests to provide oral testimony and seven written comments, which are posted to the [PDAB website](#). View the public comments in the meeting video at minute [01:25:46](#).

Vote for final adoption of insulin product: The board voted for the final adoption of the list of insulin products that will be submitted to the Oregon Legislature. Chair Patterson made the motion and Amy Burns provided a second. View the motion in the meeting video at minute [01:30:28](#).

MOTION to adopt a final list of insulin products, which includes Humulin R U-500 KwikPen, that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.

Board Vote:

Yes: Amy Burns, Daniel Hartung, Robert Judge, John Murray, Vice Chair Shelley Baily, Chair Akil Patterson

No: None

Motion passed 6-0

Chair Patterson announced his resignation from the board. He will continue serving until a replacement board member has been appointed. View the chair's announcement in the meeting video at minute [01:34:00](#).